斯達特(Starter)，國產抗體專家，
產品別名: FITC Mouse Anti-Human CD161 Antibody (S-R581)

CD161, also known as KLRB1 or NKRP1A, is a C-type lectin-like receptor primarily expressed on the surface of natural killer (NK) cells and a subset of T cells, including mucosal-associated invariant T (MAIT) cells and some CD8+ T cells. It is particularly enriched in immune cells located in mucosal sites such as the gut and liver. CD161 binds to its ligand, lectin-like transcript 1 (LLT1, also known as CLEC2D), and this interaction can have both inhibitory and costimulatory effects on immune cells. In the context of cancer immunotherapy, CD161 has been identified as a potential inhibitory receptor in glioma-infiltrating T cells. Its activation by CLEC2D on tumor or immunosuppressive cells can dampen T cell responses against cancer cells. Recent studies suggest that blocking the CD161-CLEC2D interaction may enhance T cell-mediated antitumor activity, making CD161 a promising target for cancer immunotherapy.

杭州斯達特專注于抗體研發和制造，其核心團隊深耕抗體研發十五年，提供優質的抗體、蛋白、試劑盒和定制服務，包括科研抗體、CDx和IVD抗原和抗體原料、一步法ELISA試劑盒、鼠兔通用二抗試劑盒以及其他用途的免疫試劑整體解決方案。公司建立了多物種單B細胞抗體開發平臺（兔單抗，鼠類單抗等）、傳統鼠單抗、重組蛋白表達平臺及完善的抗體應用驗證和檢測體系（包括免疫層析，酶聯免疫，流式分析，免疫組化，免疫印跡，免疫熒光，免疫沉淀等）。已正式通過歐盟98/79/EC認證、ISO9001認證和ISO13485認證。 官網點擊查詢：www.starter-bio.com